



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Vascular smooth muscle cell fate and vascular remodeling: Mechanisms, therapeutic targets, and drugs, volume I

Citation for published version:

Wang, Q, Dai, X, MacRae, VE & Song, P 2022, 'Vascular smooth muscle cell fate and vascular remodeling: Mechanisms, therapeutic targets, and drugs, volume I', *Frontiers in pharmacology*, vol. 13, 989689. <https://doi.org/10.3389/fphar.2022.989689>

Digital Object Identifier (DOI):

[10.3389/fphar.2022.989689](https://doi.org/10.3389/fphar.2022.989689)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Frontiers in pharmacology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





OPEN ACCESS

EDITED AND REVIEWED BY

Francesco Rossi,
University of Campania Luigi Vanvitelli,
Italy

*CORRESPONDENCE

Qilong Wang,
wangqilong_00@tjutcm.edu.cn
Ping Song,
psong@gsu.edu

SPECIALTY SECTION

This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 08 July 2022

ACCEPTED 15 July 2022

PUBLISHED 16 August 2022

CITATION

Wang Q, Dai X, MacRae VE and Song P
(2022), Editorial: Vascular smooth
muscle cell fate and vascular
remodeling: Mechanisms, therapeutic
targets, and drugs, volume I.
Front. Pharmacol. 13:989689.
doi: 10.3389/fphar.2022.989689

COPYRIGHT

© 2022 Wang, Dai, MacRae and Song.
This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Editorial: Vascular smooth muscle cell fate and vascular remodeling: Mechanisms, therapeutic targets, and drugs, volume I

Qilong Wang^{1*}, Xiaoyan Dai², Vicky E. MacRae³ and Ping Song^{4*}

¹Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China, ²Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China, ³The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, United Kingdom, ⁴Center for Molecular and Translational Medicine, Georgia State University, Atlanta, GA, United States

KEYWORDS

VSMC, neointimal hyperplasia, vascular dilation, arterial stiffness, calcification, atherosclerosis

Editorial on the Research Topic

[Vascular smooth muscle cell fate and vascular remodeling: Mechanisms, therapeutic targets, and drugs, volume I](#)

Introduction

Vascular smooth muscle cells (VSMCs), an essential cell type of the blood vessel, are required for maintaining vascular structure and function with unique phenotypes. However, under a pathological state VSMC fate changes such as proliferation, migration, apoptosis, quiescence, senescence and trans-differentiation, can lead to altered structure and arrangement of blood vessels. This can subsequently result in the development of critical cardiovascular diseases including atherosclerosis, aneurysm, hypertension, vascular calcification and arterial stiffness. Currently, there is limited therapy to prevent VSMC phenotype switching and vascular remodeling. Therefore, investigating the cellular and molecular basis of VSMC cell fate change will enable the discovery of novel therapeutic targets and develop effective medicines to treat cardiovascular diseases.

To understand the underlying mechanisms of VSMC fate regulation and issue future perspectives, we actively bring together this Research Topic “*Vascular Smooth Muscle Cell Fate and Vascular Remodeling: Mechanisms, Therapeutic Targets, and Drugs*” for the readers of Frontiers in Pharmacology. This Research Topic has twelve papers, including

ten original research articles and two literature reviews, highlighting novel mechanisms and medicines underpinning VSMC fate and vascular remodeling.

VSMCs and neointimal hyperplasia

Neointimal hyperplasia is a pathological process associated with dysregulated VSMC proliferation and migration within the vessel during atherosclerosis and in-stent restenosis. Zhang et al. showed that VSMC-specific deletion of lethal giant larvae 1 (LGL1), which functions as cell polarity regulator and tumor suppressor, caused promotion of neointimal hyperplasia *in vivo*. Moreover, LGL1 knockdown enhanced the proliferation and migration of VSMCs *in vitro*. The authors proposed that this effect may be mediated by the loss of LGL1-STAT3 binding and enhanced STAT3-mediated proliferation/migration-related gene transcription.

In-stent restenosis is a common complication following stent placement. Identifying the biomarker for the onset of in-stent restenosis in the patients is critical after stent implantation. Guo et al. (2022) recruited patients from 6 months and 2 years post percutaneous coronary intervention (PCI) and measured serum homocysteine. The authors observed a positive correlation between homocysteine and severity of restenosis after PCI, suggesting that serum homocysteine level might be a predictive biomarker for stent restenosis severity.

Additionally, new therapeutic medicines useful for suppressing neointima formation are illustrated here. Wu et al. (2022) found that theaflavin-3,3'-digallate, a natural product isolated from black tea, attenuated neointimal hyperplasia *in vivo*. Meanwhile, theaflavin-3,3'-digallate (TF3) decreased the proliferation and migration of primary rat aortic smooth cells *in vitro*. The authors further showed that TF3 reduced phosphorylation of PDGFR β , leading to the blockage of PDGF-induced phenotypic switching of VSMCs, suggesting that TF3 might be a potential therapeutic candidate for the treatment of neointima formation.

VSMCs and vascular dilation

VSMC contraction and relaxation contributes to the function of the vessel. However, abnormal vasoconstriction and vasospasm leads to vascular disease pathogenesis, particularly hypertension, angina and stroke. Zhang et al. found that benzoyleconitine, a monoester alkaloid from *Aconitum carmichaelii*, reduced blood pressure in spontaneously hypertensive rats. Studies demonstrated that benzoyleconitine directly binds with angiotensin-converting enzymes (ACE)/ACE2 and activates ACE/ACE2 activity, through virtual docking, surface plasmon resonance, enzyme activity assays and HUVEC cell culture experiments. Benzoyleconitine enhanced endothelium-dependent vasorelaxation and reduced vascular inflammation, and therefore maybe a potential

modulator of the renin-angiotensin system for the treatment of hypertension.

Cui et al. (2022) found that allicin, an active molecular derived from garlic, exaggerated coronary artery relaxation induced by 5-hydroxytryptamine (5-HT), 9,11-dideoxy-9 α ,11 α -methanoepoxy-prosta-5Z,13E-dien-1-oic acid (U46619), or endothelin-1 (ET-1). Allicin relaxed VSMCs via activation of the ATP-sensitive potassium (K_{ATP}) channels. Moreover, Allicin enhanced hydrogen sulfide (H_2S) production and cystathionine- γ -lyase levels in serum and myocardial tissue. These molecules may be involved in the mechanism of allicin action in acute myocardial infarction.

Traditional Chinese medicine has been used to treat cardiovascular disease for thousands of years. Guo et al. (2022) demonstrated that Danggui Buxue Decoction, consisting of *Angelicae Sinensis Radix* and *Astragali Radix*, induces a relaxation effect on rat middle cerebral artery. Danggui Buxue decoction, *Angelicae Sinensis Radix*, and *Astragali Radix* extracts relax KCl and U46619-contracted middle cerebral artery, with activation of K_{ATP} and K_{ir} channels underpinning this mechanism. Moreover, extracellular Ca^{2+} influx and internal Ca^{2+} from organelles also contribute to the action of Danggui Buxue Decoction. Fan et al. (2021) have further found that SaiLuoTong capsule attenuated cerebral infarction and neurological deficit in the middle cerebral artery occlusion rat model. SaiLuoTong capsule increased tight junction proteins via upregulation of a Nrf2-mediated anti-oxidative pathway in vascular endothelium and bone marrow microvascular endothelial cells, suggesting that SaiLuoTong capsule's therapeutic effect on brain ischemia might be related to Nrf2-dependent endothelial cell protection.

VSMCs and arterial stiffness

Arterial stiffness refers to the loss of elastic characteristics within the arterial wall, leading to systolic blood pressure and cardiac dysfunction. VSMC collagen deposition and hypercontraction contribute to arterial stiffness. Previous studies have measured the intrinsic mechanical properties of VSMCs to evaluate cell stiffness using atomic force microscopy. Ahmed et al. (2022) have provided a novel technique to record the tensegrity model of cellular mechanics using polyacrylamide hydrogels to mimic the physiological stiffness of the aortic wall. Angiotensin II inhibited the VSMC morphology and enhanced traction stress, whereas colchicine increased VSMC morphology, suggesting that VSMC morphology and actomyosin activity are the major reason for the contractile response. Moreover, microtubule destabilization by paclitaxel blocked the angiotensin II-induced morphology change, revealing that microtubules are essential in regulating the morphology and contractility of the isolated VSMCs.

Zhang et al. found that ginsenoside Rb1, a natural compound from ginseng, improved aortic stiffness in diabetic mice. Rb1 regulated pulse pressure and aortic compliance and

restored acetylcholine-induced endothelium-dependent vasorelaxation. Rb1 induced phosphorylation of AMPK and inhibited TGF β 1/smad2/3, ROS production, and MMP2/9 expression. Moreover, AMPK silencing blocked Rb1-mediated reduction of collagen deposition, fibronectin expression, and elastic fiber alignment, suggesting that Rb1 ameliorates diabetic arterial stiffness via AMPK activation.

VSMCs and arterial calcification

Arterial calcification is characterized by the deposition of calcium phosphate crystals in the artery wall. VSMC transdifferentiation and mineralization can induce arterial calcification. Daprodustat is a medicine employed to increase erythropoiesis via stabilization of HIF1 α . Toth et al. (2022) demonstrated that Daprodustat increased aortic calcification in a high phosphate-induced chronic kidney disease mice model. Daprodustat could stabilize HIF1 α and HIF2 α to accelerate medial calcification, suggesting that there is a possible risk that Daprodustat treatment could accelerate medial calcification in CKD patients with hyperphosphatemia.

VSMCs and atherosclerosis

VSMCs are the primary source of plaque cells and extracellular matrix in both early- and late-stage atherosclerosis. Li et al. (2022) have reviewed the effect of extracellular vesicles on VSMC in atherosclerosis. The extracellular vesicles could be secreted by multiple cell types, including endothelial cells, macrophages, and mesenchymal stem cells. Extracellular vesicles are essential for intercellular communication via their contents, such as miRNA and lncRNA. The author suggested that extracellular vesicles might function as diagnostic indicators of atherosclerosis and drug vectors. Wang et al. (2022) have summarized the role of IL-17 in the pathogenesis of rheumatoid arthritis and atherosclerosis. Serum IL-17 level is significantly upregulated in patients with rheumatoid arthritis and atherosclerosis. Then, IL-17 regulates proliferation, migration, and apoptosis of vascular endothelial cells and VSMC, leading to cytokine production and the development of atherosclerosis. IL-17 also regulates bone destruction and synovial hyperplasia. Therefore, IL-17 might be used as a potential therapeutic target for the

occurrence and development of cardiovascular disease in patients with rheumatoid arthritis.

In conclusion, this Research Topic provides valuable articles describing novel molecular mechanisms and innovative therapeutic medicines to treat cardiovascular diseases.

Author contributions

QW, XD, and PS wrote the manuscript. VM revised the manuscript. All the authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

This work was supported by grants from Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine, China (ZYYCXTD-C-202203) and Science and Technology Program of Tianjin, China (21ZYJDC00080) to QW; the Natural Science Foundation of Guangdong (2022A1515012502) to XD; Biotechnology and Biological Sciences Research Council (BBSRC) in the form of an Institute Strategic Programme Grant (BB/J004316/1) to VM; and National Heart, Lung, and Blood Institute (HL140954) to PS.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Ahmed, S., Johnson, R. T., Solanki, R., Afewerki, T., Wostear, F., and Warren, D. T. (2022). Using polyacrylamide hydrogels to model physiological aortic stiffness reveals that microtubules are critical regulators of isolated smooth muscle cell morphology and contractility. *Front. Pharmacol.* 13, 836710. doi:10.3389/fphar.2022.836710

Cui, T., Liu, W., Yu, C., Ren, J., Li, Y., Shi, W., et al. (2022). Protective effects of allicin on acute myocardial infarction in rats via hydrogen sulfide-mediated regulation of coronary arterial vasomotor function and myocardial calcium transport. *Front. Pharmacol.* 12, 752244. doi:10.3389/fphar.2021.752244

Fan, X.-D., Yao, M.-J., Yang, B., Han, X., Zhang, Y.-H., Wang, G.-R., et al. (2021). Chinese herbal preparation SaiLuoTong alleviates brain ischemia via Nrf2 antioxidation pathway-dependent cerebral microvascular protection. *Front. Pharmacol.* 12, 748568. doi:10.3389/fphar.2021.748568

Guo, J., Gao, Y., Ahmed, M., Dong, P., Gao, Y., Gong, Z., et al. (2022). Serum homocysteine level predictive capability for severity of restenosis post percutaneous coronary intervention. *Front. Pharmacol.* 13, 816059. doi:10.3389/fphar.2022.816059

Li, T., Wang, B., Din, H., Chen, S., Cheng, W., Li, Y., et al. (2022). Effect of extracellular vesicles from multiple cells on vascular smooth muscle cells in atherosclerosis. *Front. Pharmacol.* 13, 857331. doi:10.3389/fphar.2022.857331

Toth, A., Csiki, D. M., Nagy, B., Jr, Balogh, E., Lente, G., Ababneh, H., et al. (2022). Daprodustat accelerates high phosphate-induced calcification through the activation of HIF-1 signaling. *Front. Pharmacol.* 13, 798053. doi:10.3389/fphar.2022.798053

Wang, J., He, L., Li, W., and Lv, S. (2022). A role of IL-17 in rheumatoid arthritis patients complicated with atherosclerosis. *Front. Pharmacol.* 13, 828933. doi:10.3389/fphar.2022.828933

Wu, Y., Chen, M., Chen, Z., Shu, J., Zhang, L., Hu, J., et al. (2022). Theaflavin-3,3'-digallate from black tea inhibits neointima formation through suppression of the PDGFR β pathway in vascular smooth muscle cells. *Front. Pharmacol.* 13, 861319. doi:10.3389/fphar.2022.861319